{
  "model": "gemini-flash-latest",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/gemini-flash-latest-tumor-vaccine-ici-run-1",
  "success": false,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 93844,
  "agentCostUsd": 0,
  "graderCostUsd": 0.02148825,
  "totalCostUsd": 0.02148825,
  "agentUsage": {
    "promptTokens": 50610,
    "cachedTokens": 34798,
    "responseTokens": 3220,
    "thinkingTokens": 6785,
    "totalTokens": 60615
  },
  "graderUsage": {
    "promptTokens": 4175,
    "cachedTokens": 0,
    "responseTokens": 418,
    "thinkingTokens": 595,
    "totalTokens": 5188
  },
  "totalUsage": {
    "promptTokens": 54785,
    "cachedTokens": 34798,
    "responseTokens": 3638,
    "thinkingTokens": 7380,
    "totalTokens": 65803
  },
  "modelVersions": [
    "gemini-flash-latest"
  ],
  "agentFinalText": "Task complete.\n\n### Completion Checklist\n- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral delivery of an mRNA vaccine sensitize tumors to immune checkpoint blockade by creating an interferon-rich inflammatory state?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse Combination Efficacy Cohort\",\n      \"sample_size_or_observations\": \"78 mice\",\n      \"description\": \"Tumor-bearing mice receiving the combined treatment of intratumoral mRNA vaccine and anti-PD-L1 checkpoint blockade to assess efficacy.\"\n    },\n    {\n      \"id\": \"mouse-control-groups\",\n      \"label\": \"Mouse Control Cohorts\",\n      \"sample_size_or_observations\": \"84 mice\",\n      \"description\": \"Tumor-bearing mice used for matched controls, including vaccine-only, ICI-only, and vehicle groups.\"\n    },\n    {\n      \"id\": \"human-retrospective-ici\",\n      \"label\": \"Human Retrospective Metastatic Cohort\",\n      \"sample_size_or_observations\": \"130 patients total\",\n      \"description\": \"Metastatic cancer patients receiving ICI treatment, divided into vaccinated (43 patients) and unvaccinated (87 patients) subgroups based on prior SARS-CoV-2 mRNA vaccination status.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination enhances the effectiveness of immune checkpoint blockade therapy.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers type I interferon signaling, which in turn leads to a broader presentation of tumor antigens on MHC-I.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"The study supports a biologically coherent hypothesis for combination therapy, but clinical application requires prospective randomized studies for validation.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.\",\n          \"line_ref\": \"L56\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Vaccination timing relative to ICI initiation varied across patients.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Intratumoral mRNA vaccination makes the tumor microenvironment more targetable by increasing PD-L1 expression and subsequent T-cell infiltration.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"mRNA Vaccines Can Sensitize Tumors to Immune Checkpoint Blockade by Triggering a Local Interferon Response\",\n  \"plain_language_summary\": \"The study explores a new way to make cancer immunotherapy, specifically immune checkpoint blockade (ICI), more effective. Many tumors do not respond to ICI because they are 'cold,' lacking strong immune signals. Researchers found that delivering an mRNA vaccine directly into tumors in mouse models created a strong, localized inflammatory state driven by Type I interferons (3.1 vs 1.0 normalized units). This inflammation led to a significant increase in the display of tumor antigens (62.3% vs 37.3% of tumor proteins represented) and increased PD-L1 expression (2.4x fold-change). This effective sensitization was corroborated by a small, retrospective analysis of 130 metastatic cancer patients treated with ICI. In this human cohort, patients who had received a prior SARS-CoV-2 mRNA vaccine showed improved survival compared to those who had not (p=0.01). The findings provide a biologically coherent path to improve ICI responses, but the human data is observational and preliminary, meaning large, randomized clinical trials are required before this approach can be used in clinics.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination creates an interferon-rich inflammatory state in tumors, a mechanism that can sensitize them to immune checkpoint blockade (ICI) in mouse models.\",\n    \"The sensitization mechanism involves a significant expansion of the tumor's antigen presentation landscape, making it more visible to the immune system's T-cells.\",\n    \"A retrospective analysis suggests a clinical correlation between prior SARS-CoV-2 mRNA vaccination and improved survival outcomes for metastatic patients undergoing ICI treatment.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human survival data is from a retrospective and non-randomized study, meaning the observed association may be due to other confounding factors and is not proof of cause and effect.\",\n    \"The timing of vaccination relative to the start of ICI treatment varied significantly across the human patients, limiting the interpretation of the optimal treatment window.\",\n    \"The promising results from mouse models need to be confirmed in diverse human tumors before being generalized to all cancer patients.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune Checkpoint Inhibitors (ICI)\",\n      \"definition\": \"A type of cancer drug that blocks inhibitory signals on immune cells or tumor cells (like PD-L1), thereby allowing the immune system to recognize and attack the tumor more effectively.\"\n    },\n    {\n      \"term\": \"Type I Interferon\",\n      \"definition\": \"A potent immune signaling protein that is rapidly produced in response to viral components like mRNA, driving a strong localized inflammatory and anti-tumor immune response.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A protein complex on the surface of most cells that displays fragments of proteins (antigens) to T-cells, which is crucial for immune surveillance and tumor recognition.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The complete collection of tumor antigens displayed on the surface of a cancer cell that can potentially be recognized by the immune system.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will prospective, randomized clinical trials confirm the survival benefit observed in the retrospective human cohort and prove the strategy's clinical value?\",\n    \"What is the optimal delivery method, dose, and timing for intratumoral mRNA vaccination in combination with systemic ICI in a safe and effective clinical protocol?\",\n    \"Can a dedicated, tumor-specific mRNA vaccine be designed to produce a stronger and more durable anti-tumor effect than an unrelated viral vaccine?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-14T12:57:09.749Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-14T12:57:13.008Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-14T12:57:16.348Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-14T12:57:19.556Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-14T12:57:23.871Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-14T12:57:30.274Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-14T12:57:35.718Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-14T12:57:45.618Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-14T12:57:54.516Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-14T12:58:07.557Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-14T12:58:16.046Z"
      }
    ]
  },
  "grader": {
    "model": "gpt-5.2",
    "value": {
      "verdict": "fail",
      "scores": {
        "faithfulness": 3,
        "coverage": 4,
        "usefulness": 5
      },
      "critical_issues": [
        "Causal overstatement in claim_audit.json (C04): it asserts that increased PD-L1 expression leads to “subsequent T-cell infiltration” with “strong” strength. The report supports that PD-L1 pathway activity increases (L45) and that CD8+ density increases (L33), but it does not establish PD-L1 upregulation as the causal driver of infiltration. This is a mechanistic interpretation beyond what is explicitly supported in the report.",
        "Evidence-strength calibration is too strong in multiple places. For example, claim_audit.json marks mechanistic chains as “strong” (C02, C04) despite the report’s explicit caveat that some mechanistic readouts were strongest only in specific model systems and not uniform across settings (L53). That caveat is included as text in C02 but the strength label still overstates confidence given L53.",
        "study_overview.json omits a key limitation present in the report: that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings (L53). This is part of the paper’s core threats-to-validity section (L48–L53) and should be captured in the high-level limitations list for downstream review."
      ],
      "summary": "The JSON outputs largely track the report’s quantitative values and include valid line references for the numeric findings and main null/control results (L28–L39). However, they fail the grading criteria due to overconfident/causal phrasing and strength labeling not fully calibrated to the report’s stated limitations (notably L53), and because one key caveat from the threats-to-validity section is missing from the study overview limitations. These issues could mislead downstream users into infেচ"
    }
  }
}
